Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
// Gwendolyn J. McGinnis 1, 2, 3 , David Friedman 4 , Kristina H. Young 4 , Eileen Ruth S. Torres 2 , Charles R. Thomas Jr 3 , Michael J. Gough 3, 4 , Jacob Raber 2, 3, 5, 6 1 Howard Hughes Medical Institute, Oregon Health and Science University, Portland, OR 2 Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 3 Department of Radiation Medicine, Oregon Health and Science University, Portland, OR 4 Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR 5 Department of Neurology, Oregon Health and Science University, Portland, OR 6 Division of Neuroscience, Oregon National Primate Research Center, Portland, OR Correspondence to: Jacob Raber, email: raberj@ohsu.edu Keywords: neuroinflammation, cancer-related neurological dysfunction, microglia, immunotherapy, radiotherapy Received: June 21, 2016 Accepted: November 14, 2016 Published: November 24, 2016 ABSTRACT Background: Cancer patients often report behavioral and cognitive changes following cancer treatment. These effects can be seen in patients who have not yet received treatment or have received only peripheral (non-brain) irradiation. Novel treatments combining radiotherapy (RT) and immunotherapy (IT) demonstrate remarkable efficacy with respect to tumor outcomes by enhancing the proinflammatory environment in the tumor. However, a proinflammatory environment in the brain mediates cognitive impairments in other neurological disorders and may affect brain function in cancer patients receiving these novel treatments. Currently, gaps exist as to whether these treatments impact the brain in individuals with or without tumors and with regard to the underlying mechanisms. Results: Combined treatment with precision RT and checkpoint inhibitor IT achieved control of tumor growth. However, BALB/c mice receiving combined treatment demonstrated changes in measures of anxiety levels, regardless of tumor status. C57BL/6J mice with tumors demonstrated increased anxiety, except following combined treatment. Object recognition memory was impaired in C57BL/6J mice without tumors following combined treatment. All mice with tumors showed impaired object recognition, except those treated with RT alone. Mice with tumors demonstrated impaired amygdala-dependent cued fear memory, while maintaining hippocampus-dependent context fear memory. These behavioral alterations and cognitive impairments were accompanied by increased microglial activation in mice receiving immunotherapy alone or combined with RT. Finally, based on tumor status, there were significant changes in proinflammatory cytokines (IFN-γ, IL-6, IL-5, IL-2, IL-10) and a growth factor (FGF-basic). Materials and Methods: Here we test the hypothesis that IT combined with peripheral RT have detrimental behavioral and cognitive effects as a result of an enhanced proinflammatory environment in the brain. BALB/c mice with or without injected hind flank CT26 colorectal carcinoma or C57BL/6J mice with or without Lewis Lung carcinoma were used for all experiments. Checkpoint inhibitor IT, using an anti-CTLA-4 antibody, and precision CT-guided peripheral RT alone and combined were used to closely model clinical treatment. We assessed behavioral and cognitive performance and investigated the immune environment using immunohistochemistry and multiplex assays to analyze proinflammatory mediators. Conclusions: Although combined treatment achieved tumor growth control, it affected the brain and induced changes in measures of anxiety, cognitive impairments, and neuroinflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., & Meader, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70002-x · Cited by 2,449 · cited 2×
“Symptoms of anxiety and depression are significantly more common in cancer patients than in the general population [3, 71].”
BackgroundInflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742 · cited 1×
“IFN-γ is a critical inflammatory mediator produced by chronically activated macrophages [82].”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000 · cited 2×
“These behavioral changes and cognitive impairments are most likely at least in part mediated by the immune environment in the brain [3, 19, 51, 53, 74].”
BackgroundUsing the rat forced swim test to assess antidepressant-like activity in rodents
Slattery, D. A., & Cryan, J. F. (2012) · Nature Protocols · doi:10.1038/nprot.2012.044 · Cited by 903
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865 · cited 1×
“Increased microglial activation, especially when chronic, has been associated with neurodegenerative conditions [18].”
BackgroundDębiec, J., & Ledoux, J. E. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.08.018 · Cited by 602
Torres-Platas, S. G., Cruceanu, C., Chen, G. G., Turecki, G., & Mechawar, N. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.007 · Cited by 545 · cited 1×
“These differences are particularly striking in the hippocampus, which is similar to findings of neuroinflammation in chronic stress and depression [20, 22].”
Result
Cited by
Lange, M., Joly, F., Vardy, J., Ahles, T., Dubois, M., Tron, L., Winocur, G., De Ruiter, M. B., & Castel, H. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz410 · Cited by 667
Parkinson disease and the immune system - Associations, mechanisms and therapeutics
Tan, E.-K., Chao, Y.-X., West, A., Chan, L.-L., Poewe, W., & Jankovic, J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0344-4 · Cited by 457
Choi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 298
Raber, J., Yamazaki, J., Torres, E. R. S., Kirchoff, N., Stagaman, K., Sharpton, T., Turker, M. S., & Kronenberg, A. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00179 · Cited by 78
Self-citationTorres, E. R. S., Akinyeke, T., Stagaman, K., Duvoisin, R. M., Meshul, C. K., Sharpton, T. J., & Raber, J. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00140 · Cited by 38
Self-citation
Metadata
- Authors
- McGinnis, G. J., Friedman, D., Young, K. H., Torres, E. R. S., Thomas, C. R., Gough, M. J., & Raber, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-11-24
- Volume
- 8
- Issue
- 6
- Pages
- 9155-9173
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2552711925
- Cited by
- 69
- References
- 18
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.